Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | TYMS | P04818 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | MAPK14 | Q16539 | 4/20 | 0.35 |
| ▸ | DPP4 | P27487 | 1/20 | 0.34 |
| ▸ | RORC | P51449 | 3/20 | 0.33 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.33 |
| ▸ | MYC | P01106 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.33 |
| ▸ | MAOA | P21397 | 1/20 | 0.33 |
| ▸ | BLVRB | P30043 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366132 | 0.93 | TTR (0.43) | TTRTDP1MAPK14DPP4RORC | |
| SCHEMBL12366211 | 0.88 | IL2 (0.41) | MAPK14 | |
| SCHEMBL12366040 | 0.87 | TTR (0.39) | TTRTDP1MAPK14RORC | |
| SCHEMBL12366307 | 0.86 | TDP1 (0.38) | TTRTDP1MAPK14MRGPRX4 | |
| SCHEMBL12366614 | 0.86 | HTR5A (0.48) | — | |
| SCHEMBL12390324 | 0.85 | LMNA (0.44) | TTRTDP1RORCMRGPRX4 | |
| SCHEMBL12366277 | 0.85 | TDP1 (0.39) | TTRTYMSTDP1MRGPRX4MYC | |
| SCHEMBL12389997 | 0.84 | RORC (0.37) | TTRTDP1DPP4RORCMRGPRX4 | |
| SCHEMBL12366301 | 0.84 | TTR (0.36) | TTRTDP1DPP4RORCMAOA | |
| SCHEMBL12366143 | 0.83 | TDP1 (0.39) | TTRTDP1DPP4MAOABLVRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | TTR 3588/4885TYMS 3575/4885TDP1 378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.